David Powell, MD
Cardiovascular Disease · Springfield, NJNPI 1013902477
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $147,618 of the $162,181 with a category attached, or 91.0%. Novo Nordisk accounts for 88.9% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2022 at $62,760 and has fallen 67.3% since, to $20,499 in 2025. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 313 payments — averaging $518.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$144K
- Boehringer Ingelheim$8K
- E.r. Squibb & Sons, L.L.C.$4K
- Lilly USA, LLC$3K
- Amgen$465
- Novartis$439
- plus $2K from 26 others
What the payments were for
- Consulting fees$1,4251%
- Speaking & faculty fees$147,61891%
- Travel & lodging$6,6734%
- Food & beverage$6,2884%
- Education$1770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 117 | $144,113 |
| Boehringer Ingelheim | 13 | $7,729 |
| E.r. Squibb & Sons, L.L.C. | 32 | $3,977 |
| Lilly USA, LLC | 4 | $3,100 |
| Amgen | 32 | $465 |
| Novartis | 21 | $439 |
| Sanofi-aventis U.S. LLC | 2 | $365 |
| Abbott | 5 | $284 |
| Pfizer | 18 | $279 |
| Johnson & Johnson | 14 | $200 |
| AstraZeneca | 7 | $185 |
| Bayer | 4 | $156 |
| Baxter Healthcare | 5 | $131 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $92 |
| Regeneron Healthcare Solutions, Inc. | 1 | $88 |
| Amarin Pharma, Inc. | 6 | $82 |
| Astellas Pharma US Inc | 1 | $80 |
| Heartflow, Inc. | 2 | $61 |
| Merck | 4 | $55 |
| Alnylam Pharmaceuticals Inc. | 3 | $45 |
| Boston Scientific | 2 | $39 |
| Azurity Pharmaceuticals, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Irhythm Technologies, Inc. | 2 | $28 |
| Bracco Diagnostics Inc. | 1 | $19 |
| Cvrx, Inc. | 2 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| Gilead | 1 | $15 |
| Akcea Therapeutics, Inc. | 1 | $14 |
| Althera Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$162,181 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 788 | $1,012,526 |
| VyndamaxTafamidis | 17 | $550,204 |
| OzempicSemaglutide | 225 | $354,204 |
| EntrestoSacubitril/Valsartan | 161 | $215,822 |
| JardianceEmpagliflozin | 139 | $163,587 |
| FarxigaDapagliflozin Propanediol | 117 | $142,746 |
| XareltoRivaroxaban | 91 | $116,736 |
| MounjaroTirzepatide | 54 | $82,123 |
| Repatha SureclickEvolocumab | 59 | $64,483 |
| VascepaIcosapent Ethyl | 41 | $30,669 |
| Rosuvastatin Calcium | 1,361 | $24,725 |
| Icosapent Ethyl | 55 | $23,194 |
| Praluent PenAlirocumab | 31 | $22,211 |
| KerendiaFinerenone | 17 | $14,497 |
| TrulicityDulaglutide | 11 | $14,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $279 | $1,562,730805 claims |
| Novo NordiskOzempic | $144,113 | $354,204225 claims |
| NovartisEntresto | $439 | $215,822161 claims |
| Boehringer IngelheimJardiance | $7,729 | $163,587139 claims |
| AstraZenecaFarxiga, Crestor | $185 | $147,919131 claims |
| Johnson & JohnsonXarelto | $200 | $116,73691 claims |
| Lilly USA, LLCMounjaro, Trulicity | $3,100 | $96,54765 claims |
| BayerKerendia | $156 | $14,49717 claims |
| Esperion Therapeutics, Inc.Nexlizet | $28 | $9,73715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Springfield
- Robert FishbergSpringfield$94K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.